Dear Colleagues, 

Personalized therapy is a type of targeted treatment. It helps treat a wide range of diseases such as cancer, autoimmune diseases, and immunosuppressive therapy. It has many advantages over conventional medicine. This is because it enables the selection of the optimal therapy, thereby increasing its safety and efficacy, reducing adverse drug reactions, increasing patient compliance, and reducing the cost, time, and failure rate of clinical trials. Personalized medicine owes its development to innovative therapies, advances in genomics, metabolomics and other omics sciences, and modern analytical methods. Personalized therapy uses biomarkers, including modern tools from the -omic sciences, to predict the outcome of therapy in many diseases. An example of drugs that require personalized therapy is immunosuppressive drugs used to treat organ transplant patients. These have very complex and variable pharmacokinetics. In addition, personalized therapy with these drugs is necessary because of narrow therapeutic ranges, significant variability in blood concentrations among patients, sex differences in drug metabolism, and drug interactions.

The Special Issue “Personalized drug therapy: from therapeutic drug monitoring to clinical outcome” of the International Journal of Molecular Sciences welcomes both original research and review papers. Clinical and model submissions, with biomolecular experiments and some validation data for biological experiments, respectively, are welcomed. We will consider articles in the broad field of personalized therapy. In particular, we would like to discuss the differences between targeted and personalized therapy as a new treatment and therapeutic option. It should be emphasized that before and during the personalized therapy procedure, the analysis should be focused on each patient for whom treatment is being developed. Suggested manuscript topics are listed below.

Suggested topics:

1. Drug combination effects and the impact of gene profiling on pharmacokinetics and pharmacological responses;
2. The value of biomarkers in optimizing personalized therapy, including the use of modern tools from the field of, e.g., pharmacometabolomics;
3. Correlation between drug concentration and clinical outcome;
4. Development of analytical methods based on new sorbents and their application for monitoring drug concentrations in personalized therapy.

Dr. Tomasz Pawiński
Dr. Joanna Giebułtowicz
Dr. Andrzej Czyrski
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• personalized therapy
• therapeutic drug monitoring
• pharmacokinetics variability
• liquid chromatography coupled to mass spectrometry
• immunosuppressive therapy
• anticancer therapy
• genetics
• clinical setting
• rheumatoid arthritis
• analytical methods
• metabolomics
• pharmacometabolomics
• biomarkers
• thyrosine kinase inhibitors